Smoking Cessation Aids (MCP-1591) - Global Industry Analysts, Inc.

Research Abstract

This report analyzes the worldwide markets for Smoking Cessation Aids in US$ Million by following product segments: Nicotine Gum, Nicotine Patch, Nicotine lozenges & tablets, and Others (Nicotine Inhaler, and Nasal Spray). The report provides separate comprehensive analytics for the US, Canada, Europe, and Rest of World. Annual forecasts are provided for each region for the period 2000 through 2015. The report profiles 32 companies including many key and niche players worldwide such as GlaxoSmithKline Plc, Johnson & Johnson Inc., Novartis Consumer Healthcare Inc., Perrigo Company, and Pfizer Inc. Market data and analytics are derived from primary and secondary research. Company profiles are mostly extracted from URL research and reported select online sources.

Code :	MCP-1591
Price :	$3950
Companies :	32

Pages :	177
Date :	April 2008
Market Data Tables :	65

Complimentary Copy of Study Findings:

Request a Complimentary Copy of the Study’s Key Findings, Drivers, Trends, Program Sources, and Methodology.

SMOKING CESSATION AIDS (Complete Report)

Pages : 177

$3950

I. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS

$100

Study Reliability and Reporting Limitations.....I-1

Disclaimers.....I-2

Data Interpretation & Reporting Level.....I-2

Quantitative Techniques & Analytics.....I-2

Product Definition and Scope of Study.....I-3

Smoking Cessation Aids.....I-3

Definitions.....I-3

A. Nicotine Gum .....I-3

B. Nicotine Patch.....I-4

C. Nicotine Lozenges And Tablets.....I-4

D. Others.....I-4

Nicotine Inhaler.....I-4

Nicotine Nasal Spray.....I-4

II. EXECUTIVE SUMMARY

$2250

1. Industry Outlook.....II-1

$1000

Leading Players.....II-1

Tobacco Products Industry: An Introduction.....II-1

$100

Regulations/Taxes.....II-2

Black Market.....II-2

$100

Cigarette: The Tobacco King.....II-3

Cigars: All Rolled Up.....II-3

Glut of Products Restrain Growth.....II-3

Major Cigar Tobacco Producing Regions.....II-3

$100

China Dominates the Cigarettes Sector.....II-4

Competitive Scenario.....II-4

Table 1: World Cigarettes Market for 2004 & 2005: Market Shares Based on Volume Sales of Leading Manufacturers for Philip Morris, British American Tobacco, Japan Tobacco, Imperial Tobacco, Gallaher, Reynolds American and Others (includes corresponding Graph/Chart).....II-4

$300

Table 2: World Recent Past, Current & Future Analysis for Cigarettes by Geographic Region – US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World Markets Independently Analyzed with Annual Sales Figures in Billion Units for Years 2000 2006 and 2010 (includes corresponding Graph/Chart).....II-5

Table 3: World Recent Past, Current & Future Analysis for Cigars by Geographic Region – US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World Markets Independently Analyzed with Annual Sales Figures in Million Units for Years 2000 2006 and 2010 (includes corresponding Graph/Chart).....II-5

$300

Table 4: World Recent Past, Current & Future Analysis for Cigarettes by Geographic Region – US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Billion for Years 2000 2006 and 2010 (includes corresponding Graph/Chart).....II-6

Table 5: World Recent Past, Current & Future Analysis for Cigars by Geographic Region – US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000, 2006 and 2010 (includes corresponding Graph/Chart).....II-6

$300

Why to Quit Smoking.....II-7

Secondhand Smoke.....II-7

Why Smoking is Hard to Quit.....II-7

$100

Methods of Smoking Cessations.....II-8

Cold Turkey.....II-8

$100

Drug Therapies.....II-9

Other Interventions.....II-9

Benefits of Quitting Smoking.....II-9

$200

2. World Smoking Statistics.....II-11

$100

World Smoking Statistics.....II-11

$100

3. Product Overview.....II-12

$350

Smoking Cessation Aids Defined.....II-12

Nicotine Gum.....II-12

Factors to Consider.....II-12

$100

Effectiveness of Nicotine Gum.....II-13

Nicotine Patch.....II-13

$100

Factors to Consider.....II-14

Nicotine Lozenges & Tablets.....II-14

$100

Factors to Consider.....II-15

Other Smoking Cessation Aids.....II-15

Nicotine Inhaler.....II-15

Factors to Consider.....II-15

$100

Nicotine Nasal Spray.....II-16

Factors to Consider.....II-16

Non-Nicotine Based Medications.....II-16

$100

4. Trends and Issues.....II-17

$300

Inundate Anti-Smoking Vaccines Kindles Underdeveloped Prescription Market.....II-17

Strict Regulations Deter Smoking Cessation Aids.....II-17

$100

Growing Anti Smoking Campaigns.....II-18

Health Concerns.....II-18

Corporations Initiate for Smoke Free Work Environment.....II-18

$100

Television Advertisements – Most Effective Media for Smoking Cessation.....II-19

Public Awareness through Internet.....II-19

Rising Prices of Tobacco – A Key Strategy for Quitting Smoking.....II-19

$100

5. Product Innovations/Introductions.....II-20

$100

Acomplia to Enter Smoking Cessation Market.....II-20

Fertin Phiarma and Perrigo to Launch Nicotine Gum in the US Market.....II-20

Nicødrops Unveils New Lozenge for Smoking Cessation.....II-20

Pharmacia and Takeda to Launch Smoking Cessation Aid in Japan.....II-20

Glaxo Unveils First Anti-Smoking Medicine in India.....II-20

$100

6. Recent Industry Activity.....II-21

$400

Pfizer Japan to Roll Out Champix Anti-Smoking Drug.....II-21

Inverness Medical Innovations Pockets Bio-Stat Healthcare Group.....II-21

Novartis New Smoking Cessation Aids Gets FDA’s Approval.....II-21

Johnson & Johnson Concludes Take Over of Pfizer Consumer Healthcare.....II-21

$100

Pfizer Receives FDA Approval for Smoking Cessation Medicine Chantix™.....II-22

Perrigo Obtains FDA Approval to Sell Coated Nicotine Gum.....II-22

Pfizer Receives Chinese Approval for Clinical Trials on Smoking Cessation Aid.....II-22

Pfizer Receives EC Approval for New Varenicline.....II-22

Formation of Sanofi-Aventis.....II-22

$100

AXIA Health Management Acquires Smoking Cessation Website.....II-23

Nicodrops Receives EC Approval for Smoking Cessation Aid.....II-23

Nabi Unveils Successful Phase II Results for Smoking Cessation Vaccine.....II-23

FDA Grants Approval for High Strength Bupropion.....II-23

$100

Watson Pharmaceuticals Receives Rights to Market Zyban®.....II-24

Pfizer Merges with Pharmacia.....II-24

FDA Approves Anti-Smoking Medication for OTC Sales.....II-24

GSK and Taisho to Develop Anti-Smoking Medication.....II-24

Johnson & Johnson Acquires Alza.....II-24

$100

7. Focus on Select Global Players.....II-25

$200

GlaxoSmithKline Plc (UK).....II-25

Johnson & Johnson Inc. (USA).....II-25

Novartis Consumer Healthcare Inc. (USA).....II-25

$100

Perrigo Company (USA).....II-26

Pfizer Inc. (USA).....II-26

$100

8. Global Market Perspective.....II-27

Table 6: World Recent Past, Current & Future Analysis for Smoking Cessation Aids by Geographic Region – US, Canada, Europe and Rest of World Independently Analyzed by Annual Sales in US$ Million for the Years 2000 through 2010 (includes corresponding Graph/Chart).....II-27

$300

Table 7: World Long Term Projections for Smoking Cessation Aids by Geographic Region – US, Canada, Europe and Rest of World Independently Analyzed by Annual Sales in US$ Million for the Years 2011 through 2015 (includes corresponding Graph/Chart).....II-28

$300

Table 8: World 10-Year Perspective for Smoking Cessation Aids by Geographic Region – Percentage Break down of Dollar Sales for US, Canada, Europe and Rest of the World for the Years 2003, 2008 and 2012 (includes corresponding Graph/Chart).....II-29

$300

III. MARKET

$1950

1. The United States.....III-1

$775

A. Market Analysis.....III-1

Outlook.....III-1

Cigarette Smoking Decline Stagnates in the US.....III-1

Smoking Women are at High Risk.....III-1

Tobacco Companies Spend Big on Advertising.....III-1

NRT - A Peer into the Past.....III-1

$75

Popular NRT Brands in the US Market.....III-2

Key Statistics:.....III-2

Table 9: Top 4 Nicotine Chewing Gum Brands in the US: Breakdown of Dollar Sales Through Supermarkets, Drug Stores & Discount Stores for the Year Ended November 2007 (In US$ 000).....III-2

$150

Table 10: US Market for Smoking Cessation Products: Percentage Share Breakdown of Value and Volume Sales by Product Category – Gum, Patch, Tablets, and Others (incl. Mouth Spray, Filters) for the Year Ended November 2007 (includes corresponding Graph/Chart).....III-3

Table 11: Leading NRT Brands in the US Market by Product Type in 2005: Sales in US$ Millions for Nicorette, Nicoderm CQ, Commit and Other Brands & Private Labels (includes corresponding Graph/Chart).....III-3

$150

Product Launches/Developments.....III-4

Strategic Corporate Developments.....III-4

$150

Key Players.....III-6

$225

B. Market Analytics.....III-9

Table 12: US Recent Past, Current & Future Analysis for Smoking Cessation Aids by Product Segment – Nicotine Gum, Nicotine Patches and Lozenges & Tablets Independently Analyzed by Annual Sales in US$ Million for the Years 2000 through 2010 (includes corresponding Graph/Chart).....III-9

Table 13: US Long Term Projections for Smoking Cessation Aids by Product Segment – Nicotine Gum, Nicotine Patches and Lozenges & Tablets Independently Analyzed by Annual Sales in US$ Million for the Years 2011 through 2015 (includes corresponding Graph/Chart).....III-9

$150

Table 14: US 10-Year Perspective for Smoking Cessation Aids by Product Segment – Percentage Breakdown of Dollar Sales for Nicotine Gum, Nicotine Patches and Lozenges & Tablets for the Years 2003, 2008 and 2012 (includes corresponding Graph/Chart).....III-10

$150

2. Canada.....III-11

$200

A. Market Analysis.....III-11

Outlook.....III-11

B. Market Analytics.....III-11

Table 15: Canadian Recent Past, Current & Future Analysis for Smoking Cessation Aids by Product Segment – Nicotine Gum, Nicotine Patches and Lozenges & Tablets Independently Analyzed by Annual Sales in US$ Million for the Years 2000 through 2010 (includes corresponding Graph/Chart).....III-11

$150

Table 16: Canadian Long Term Projections for Smoking Cessation Aids by Product Segment – Nicotine Gum, Nicotine Patches and Lozenges & Tablets Independently Analyzed by Annual Sales in US$ Million for the Years 2011 through 2015 (includes corresponding Graph/Chart).....III-12

Table 17: Canadian 10-Year Perspective for Smoking Cessation aids by Product Segment – Percentage Breakdown of Dollar Sales for Nicotine Gum, Nicotine Patches and Lozenges & Tablets for the Years 2003, 2008 & 2012 (includes corresponding Graph/Chart).....III-12

$150

3. Europe.....III-13

$625

A. Market Analysis.....III-13

Outlook.....III-13

Strategic Corporate Developments.....III-13

$75

Key Players.....III-14

$150

B. Market Analytics.....III-16

Table 18: European Recent Past, Current & Future Analysis for Smoking Cessation Aids by Geographic Region – France, Germany, UK, Italy, Spain & Rest of Europe Independently Analyzed by Annual Sales in US$ Million for the Years 2000 through 2010 (includes corresponding Graph/Chart).....III-16

$150

Table 19: European Long Term Projections for Smoking Cessation Aids by Geographic Region – France, Germany, UK, Italy, Spain & Rest of Europe Independently Analyzed by Annual Sales in US$ Million for the Years 2011 through 2015 (includes corresponding Graph/Chart).....III-17

$150

Table 20: European Recent Past, Current & Future Analysis for Smoking Cessation Aids by Product Segment – Nicotine Gum, Nicotine Patches, Lozenges & Tablets and Others Independently Analyzed by Annual Sales in US$ Million for the Years 2000 through 2010 (includes corresponding Graph/Chart).....III-18

Table 21: European Long Term Projections for Smoking Cessation Aids by Product Segment – Nicotine Gum, Nicotine Patches, Lozenges & Tablets and Others Independently Analyzed by Annual Sales in US$ Million for the Years 2011 through 2015 (includes corresponding Graph/Chart).....III-18

$150

Table 22: European 10-Year Perspective for Smoking Cessation Aids by Geographic Region – Percentage Breakdown of Dollar Sales for France, Germany, UK, Italy, Spain, Russia and Rest of Europe for the Years 2003, 2008 & 2012 (includes corresponding Graph/Chart).....III-19

Table 23: European 10-Year Perspective for Smoking Cessation Aids by Product Segment – Percentage Breakdown of Dollar Sales for Nicotine Gum, Nicotine Patches, Lozenges & Tablets and Others for the Years 2003, 2008 & 2012 (includes corresponding Graph/Chart).....III-19

$150

3a. France.....III-20

$225

A. Market Analysis.....III-20

Outlook.....III-20

B. Market Analytics.....III-20

Table 24: French Recent Past, Current & Future Analysis for Smoking Cessation Aids by Product Segment – Nicotine Gum, Nicotine Patches, Lozenges & Tablets and Others Independently Analyzed by Annual Sales Figures in US$ Million for the Years 2000 through 2010 (includes corresponding Graph/Chart).....III-20

$150

Table 25: French Long Term Projections for Smoking Cessation Aids by Product Segment – Nicotine Gum, Nicotine Patches, Lozenges & Tablets, and Others Independently Analyzed by Annual Sales in US$ Million for the Years 2011 through 2015 (includes corresponding Graph/Chart).....III-21

Table 26: French 10-Year Perspective for Smoking Cessation Aids by Product Segment – Percentage Breakdown of Dollar Sales for Nicotine Gum, Nicotine Patches, Lozenges & Tablets, and Others for the Years 2003, 2008 and 2012 (includes corresponding Graph/Chart).....III-21

$150

3b. Germany.....III-22

$225

A. Market Analysis.....III-22

Outlook.....III-22

B. Market Analytics.....III-22

Table 27: German Recent Past, Current & Future Analysis for Smoking Cessation aids by Product Segment – Nicotine Gum, Nicotine Patches, Lozenges & Tablets, and Other Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart).....III-22

$150

Table 28: German Long Term Projections for Smoking Cessation Aids by Product Segment – Nicotine Gum, Nicotine Patches, Lozenges & Tablets, and Others Independently Analyzed by Annual Sales in US$ Million for the Years 2011 through 2015 (includes corresponding Graph/Chart).....III-23

Table 29: German 10-Year Perspective for Smoking Cessation aids by Product Segment – Percentage Breakdown of Value Sales for Nicotine Gum, Nicotine Patches, Lozenges & Tablets, and Other Markets for 2003, 2008 and 2012 (includes corresponding Graph/Chart).....III-23

$150

3c. The United Kingdom.....III-24

$225

A. Market Analysis.....III-24

Outlook.....III-24

Table 30: Leading OTC-NRT Brands by Company in the UK in 2005: Percentage Breakdown of Value Sales for Nicorette, Niquitin CQ, Nicotinell and Others (includes corresponding Graph/Chart).....III-24

Table 31: NRT Advertisement Expenditure by Leading Companies in the UK in 2005: Percentage Breakdown for Pfizer, GlaxoSmithKline, Novartis and Others (includes corresponding Graph/Chart).....III-24

$150

B. Market Analytics.....III-25

Table 32: UK Recent Past, Current & Future Analysis for Smoking Cessation Aids by Product Segment – Nicotine Gum, Nicotine Patches, Lozenges & Tablets and Others Independently Analyzed by Annual Sales in US$ Million for the Years 2000 through 2010 (includes corresponding Graph/Chart).....III-25

$150

Table 33: UK Long Term Projections for Smoking Cessation Aids by Product Segment – Nicotine Gum, Nicotine Patches, Lozenges & Tablets, and Others Independently Analyzed by Annual Sales in US$ Million for the Years 2011 through 2015 (includes corresponding Graph/Chart).....III-26

Table 34: UK 10-Year Perspective for Smoking Cessation Aids by Product Segment – Percentage Breakdown of Dollar Sales for Nicotine Gum, Nicotine Patches, Lozenges & Tablets and Others for the Years 2003,2008 and 2012 (includes corresponding Graph/Chart).....III-26

$150

3d. Italy.....III-27

$225

A. Market Analysis.....III-27

Outlook.....III-27

B. Market Analytics.....III-27

Table 35: Italian Recent Past, Current & Future Analysis for Smoking Cessation Aids by Product Segment – Nicotine Gum, Nicotine Patches, Lozenges and Tablets and Others Independently Analyzed by Annual Sales in US$ Million for the Years 2000 through 2010 (includes corresponding Graph/Chart).....III-27

$150

Table 36: Italian Long Term Projections for Smoking Cessation Aids by Product Segment – Nicotine Gum, Nicotine Patches, Lozenges & Tablets, and Others Independently Analyzed by Annual Sales in US$ Million for the Years 2011 through 2015 (includes corresponding Graph/Chart).....III-28

Table 37: Italian 10-Year Perspective for Smoking Cessation Aids by Product Segment – Percentage Breakdown of Dollar Sales for Nicotine Gum, Nicotine Patches, Lozenges & Tablets and Others for the Years 2003, 2008 and 2012 (includes corresponding Graph/Chart).....III-28

$150

3e. Spain.....III-29

$225

A. Market Analysis.....III-29

Outlook.....III-29

B. Market Analytics.....III-29

Table 38: Spanish Recent Past, Current & Future Analysis for Smoking Cessation Aids by Product Segment – Nicotine Gum, Nicotine Patches, Lozenges & Tablets and Others Independently Analyzed by Annual Sales in US$ Million for the Years 2000 through 2010 (includes corresponding Graph/Chart).....III-29

$150

Table 39: Spanish Long Term Projections for Smoking Cessation Aids by Product Segment – Nicotine Gum, Nicotine Patches, Lozenges & Tablets, and Others Independently Analyzed by Annual Sales in US$ Million for the Years 2011 through 2015 (includes corresponding Graph/Chart).....III-30

Table 40: Spanish 10-Year Perspective for Smoking Cessation Aids by Product Segment – Percentage Breakdown of Dollar Sales for Nicotine Gum, Nicotine Patches, Lozenges & Tablets and Others for the Years 2003, 2008 and 2012 (includes corresponding Graph/Chart).....III-30

$150

3f. Rest of Europe.....III-31

$225

A. Market Analysis.....III-31

Outlook.....III-31

B. Market Analytics.....III-31

Table 41: Rest of Europe Recent Past, Current & Future Analysis for Smoking Cessation Aids by Product Segment – Nicotine Gum, Nicotine Patches, Lozenges & Tablets and Others Independently Analyzed by Annual Sales in US$ Million for the Years 2000 through 2010 (includes corresponding Graph/Chart).....III-31

$150

Table 42: Rest of Europe Long Term Projections for Smoking Cessation Aids by Product Segment – Nicotine Gum, Nicotine Patches, Lozenges & Tablets, and Others Independently Analyzed by Annual Sales in US$ Million for the Years 2011 through 2015 (includes corresponding Graph/Chart).....III-32

Table 43: Rest of Europe 10-Year Perspective for Smoking Cessation Aids by Product Segment – Percentage Breakdown of Dollar Sales for Nicotine Gum, Nicotine Patches, Lozenges & Tablets and Others for the Years 2003, 2008 and 2012 (includes corresponding Graph/Chart).....III-32

$150

4. Rest of World.....III-33

$375

A. Market Analysis.....III-33

Outlook.....III-33

Smoking Statistics in China.....III-33

Barriers to Promote Smoking Cessation in the Developing World.....III-33

Economic Factors.....III-33

Inadequate Policies to Support Cessation.....III-33

$75

Low Perception of Risk among Public and Policy Makers.....III-34

Poor Healthcare Systems and Infrastructure.....III-34

Lack of Technology.....III-34

Strategic Corporate Developments.....III-34

$75

Product Launches.....III-35

$75

B. Market Analytics.....III-36

Table 44: Rest of World Recent Past, Current & Future Analysis for Smoking Cessation Aids – Annual Sales in US$ Million for the Years 2000 through 2010 (includes corresponding Graph/Chart).....III-36

Table 45: Rest of World Long Term Projections for Smoking Cessation Aids – Annual Sales in US$ Million for the Years 2011 through 2015 (includes corresponding Graph/Chart).....III-36

$150

IV. COMPETITIVE LANDSCAPE

100

$995

Total Companies Profiled: 32 (including Divisions/Subsidiaries - 37)
Region/Country                 Players
The United States                 19
Canada                             3
Japan                              4
Europe                             9 
     France                        2
     The United Kingdom            4
     Rest of Europe                3 
Asia-Pacific (Excluding Japan)     1
Middle East                        1

Click here to request a full table of contents and more details on this project.

SMOKING CESSATION AIDS - A GLOBAL STRATEGIC BUSINESS REPORT

Research Abstract

Complimentary Copy of Study Findings:

TABLE OF CONTENTS

SMOKING CESSATION AIDS - A GLOBAL STRATEGIC BUSINESS REPORT stLight.options({ publisher:'12345' });

Research Abstract

Complimentary Copy of Study Findings:

TABLE OF CONTENTS

SMOKING CESSATION AIDS - A GLOBAL STRATEGIC BUSINESS REPORT